Blockchain Registration Transaction Record

Creative Biolabs Enhances Antibody Functionality with Innovative ADCC Technology and Fc Engineering

Creative Biolabs introduces industry-leading platform for IgG1 monoclonal antibody analysis, offering innovative glycosylation profiling and Fc region characterization services. Advancements in ADCC technology and Fc engineering improve antibody functionality for safer and more effective therapeutics.

This news matters as Creative Biolabs' cutting-edge advancements in antibody analysis and engineering have the potential to revolutionize the biopharmaceutical market, leading to the development of safer and more effective therapeutic products. By focusing on glycosylation optimization and Fc region modification, the company is paving the way for enhanced antibody functionality and improved immune modulation, benefiting both patients and the pharmaceutical industry.